Compare SABA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SABA | CBIO |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 252.6M |
| IPO Year | N/A | N/A |
| Metric | SABA | CBIO |
|---|---|---|
| Price | $8.76 | $13.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | ★ 290.0K | 182.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.64 | $9.81 |
| 52 Week High | $4.42 | $21.40 |
| Indicator | SABA | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 47.55 |
| Support Level | $8.61 | $12.59 |
| Resistance Level | $8.86 | $16.35 |
| Average True Range (ATR) | 0.15 | 1.08 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 69.36 | 18.99 |
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.